EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Comparison of anti‐nucleocapsid antibody assays for the detection of SARS‐CoV‐2 Omicron vaccine breakthroughs after various intervals since the infection

David Niklas Springer, Elisabeth Reuberger, Christian Borsodi, Elisabeth Puchhammer-Stöckl, Lukas Weseslindtner iD

Journal of Medical Virology · 2023

DOI: 10.1002/jmv.29229 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Virology, 2023. Verfasst von David Niklas Springer und 4 weiteren Autor:innen. Beteiligte Einrichtung: Center for Virology, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: COVID-19 Vaccines, COVID-19. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibody assays with the nucleocapsid (NC) protein as the target antigen can identify severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infections when polymerase chain reaction (PCR) analyses are unavailable. Regarding the kinetics of NC‐specific antibodies, vaccine breakthroughs with Omicron subvariants may differ from infections with the ancestral wild‐type virus. Therefore, we evaluated which assays have the highest sensitivity for detecting NC‐specific antibodies after various intervals since breakthrough infections with an Omicron subvariant. The study included 279 samples from vaccinated subjects who experienced PCR‐confirmed Omicron breakthrough infections between 21 and 266 days before sampling. The samples were comparatively assessed with the Elecsys® Anti‐SARS‐CoV‐2 N (Roche), the Anti‐SARS‐CoV‐2‐NCP‐ELISA (Euroimmun), the recomLine SARS‐CoV‐2 IgG (Mikrogen), and the SARS‐CoV‐2 ViraChip IgG assays (Viramed). In the whole cohort, the Elecsys® Anti‐SARS‐CoV‐2 N assay displayed the highest sensitivity (93%, p < 0.0001), followed by the recomLine SARS‐CoV‐2 IgG assay (70%), the SARS‐CoV‐2 ViraChip IgG assay (41%) and the Anti‐SARS‐CoV‐2‐NCP‐ELISA (35%). Although measured antibody levels and time‐dependent sensitivities differed, the extent of the antibody decrease was similar among all assays. As demonstrated by this study, manufacturer‐dependent differences in the sensitivities of NC‐specific antibody assays should be considered when serology is applied to link previous SARS‐CoV‐2 infections with potential post‐COVID sequelae.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19 VaccinesCOVID-19HumansSARS-CoV-2NucleocapsidAntibodies, ViralImmunoglobulin GNucleocapsid ProteinsBreakthrough InfectionsSensitivity and Specificity

Stichwörter der Autor:innen

OmicronSARS-CoV-2antibodyassaybreakthroughnucleocapsid

Substanzen

COVID-19 VaccinesAntibodies, ViralImmunoglobulin GNucleocapsid Proteins

Autor:innen und Institutionen

  • Center for Virology, Medical University of Vienna, Vienna, Austria.

ORCID-Profile: Lukas Weseslindtner

Zitieren

APA

Springer, D. N., Reuberger, E., Borsodi, C., Puchhammer-Stöckl, E., & Weseslindtner, L. (2023). Comparison of anti‐nucleocapsid antibody assays for the detection of SARS‐CoV‐2 Omicron vaccine breakthroughs after various intervals since the infection. Journal of Medical Virology. https://doi.org/10.1002/jmv.29229

Vancouver

Springer DN, Reuberger E, Borsodi C, Puchhammer-Stöckl E, Weseslindtner L. Comparison of anti‐nucleocapsid antibody assays for the detection of SARS‐CoV‐2 Omicron vaccine breakthroughs after various intervals since the infection. Journal of Medical Virology. 2023. doi:10.1002/jmv.29229

BibTeX
@article{Springer2023,
  author = {Springer, David Niklas and Reuberger, Elisabeth and Borsodi, Christian and Puchhammer-Stöckl, Elisabeth and Weseslindtner, Lukas},
  title = {Comparison of anti‐nucleocapsid antibody assays for the detection of SARS‐CoV‐2 Omicron vaccine breakthroughs after various intervals since the infection},
  journal = {Journal of Medical Virology},
  year = {2023},
  doi = {10.1002/jmv.29229}
}
Kostenlos starten →